Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis-Reference-Cited by-同舟云学术

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Published:2022-07-29 Issue:11 Volume:77 Page:3398-3407
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Spekhorst Lotte S.¹^ORCID,Bakker Daphne¹^ORCID,Drylewicz Julia²^ORCID,Rispens Theo³,Loeff Floris⁴,Boesjes Celeste M.¹,Thijs Judith¹^ORCID,Romeijn Geertruida L. E.⁵,Loman Laura⁵,Schuttelaar Marie‐Louise⁵,van Wijk Femke²,de Graaf Marlies¹,de Bruin‐Weller Marjolein S.¹^ORCID

Affiliation:

1. Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis University Medical Center Utrecht Utrecht The Netherlands

2. Division Laboratories, Pharmacy and Biomedical Genetics, Center for Translational Immunology University Medical Center Utrecht Utrecht The Netherlands

3. Department of Immunopathology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Center University of Amsterdam Amsterdam The Netherlands

4. Sanquin Diagnostic Services Sanquin Amsterdam The Netherlands

5. Department of Dermatology University Medical Center Groningen Groningen The Netherlands

Funder

Sanofi Genzyme

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15439

Reference33 articles.

1. Atopic dermatitis